نتائج البحث - "Hussein Abdul-Hassan Tawbi"

1

Pyrexia in patients treated with dabrafenib plus trametinib across clinical trials in BRAF-mutant cancers

المؤلفون: Reinhard Dummer, Georgina V. Long, Alexander M. Menzies, Mike Lau, Keith T. Flaherty, Caroline Robert, Hiya Banerjee, Hussein Abdul-Hassan Tawbi, Dirk Schadendorf

المساهمون: University of Zurich, Schadendorf, Dirk

المصدر: European Journal of Cancer. 153:234-241

وصف الملف: 903_Schadendorf_D._et_al._Pyrexia_in_patients_treated_with_dabrafenib_plus_trametinib_across_clinical_trials_in_BRAF-mutant_cancers_EJC_2021.pdf - application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ab5475de604a2c9f9a3f5325e3ddc461Test
https://doi.org/10.1016/j.ejca.2021.05.005Test

2

Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)

المصدر: Nature Medicine. 27:301-309

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::826ffd3ff8235e1e6c027f5367069a0cTest
https://doi.org/10.1038/s41591-020-01188-3Test

3

A mathematical model for the quantification of a patient’s sensitivity to checkpoint inhibitors and long-term tumour burden

المؤلفون: Eugene J. Koay, Hussein Abdul-Hassan Tawbi, Geoffrey V. Martin, Javier Ruiz-Ramírez, George A. Calin, Karine A. Al Feghali, Dalia Elganainy, Sara Nizzero, Prashant Dogra, Caroline Chung, Vittorio Cristini, David S. Hong, Zhihui Wang, James W. Welsh, Marija Plodinec, Joseph D. Butner

المصدر: Nat Biomed Eng

مصطلحات موضوعية: 0301 basic medicine, Drug, Oncology, medicine.medical_specialty, Databases, Factual, animal diseases, media_common.quotation_subject, medicine.medical_treatment, Cell, Biomedical Engineering, Medicine (miscellaneous), chemical and pharmacologic phenomena, Bioengineering, Article, 03 medical and health sciences, Antineoplastic Agents, Immunological, 0302 clinical medicine, Immune system, Neoplasms, Internal medicine, medicine, Humans, Immune Checkpoint Inhibitors, media_common, Models, Statistical, business.industry, Cancer, Immunotherapy, biochemical phenomena, metabolism, and nutrition, Models, Theoretical, medicine.disease, Immune checkpoint, Tumor Burden, Computer Science Applications, Blockade, Clinical trial, Treatment Outcome, 030104 developmental biology, medicine.anatomical_structure, ROC Curve, Area Under Curve, Linear Models, bacteria, business, 030217 neurology & neurosurgery, Biotechnology

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::84ec391bd3fcf9822673ed2667394e0eTest
https://doi.org/10.1038/s41551-020-00662-0Test

4

Development of Immunotherapy Combination Strategies in Cancer

المؤلفون: Hussein Abdul-Hassan Tawbi, Timothy A. Yap, Eileen Parkes, Weiyi Peng, Michael A. Curran, Justin T. Moyers

المصدر: Cancer Discov

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::37ca4f20c84b2935ef4dc90a101aa013Test
https://europepmc.org/articles/PMC8178168Test/

5

426 MK-3475-U02: Phase 1/2 study of investigational agents with or without pembrolizumab versus pembrolizumab monotherapy in melanoma

المؤلفون: Sama Ahsan, Michael A. Postow, Janis M. Taube, Hussein Abdul-Hassan Tawbi, Caroline Robert, Anna C. Pavlick, Richard A. Scolyer, Scott J. Diede, Reinhard Dummer, Georgina V. Long, Michael T. Tetzlaff, Antoni Ribas, Jason J. Z. Liao

المصدر: Regular and young investigator award abstracts.

مصطلحات موضوعية: Oncology, medicine.medical_specialty, business.industry, medicine.medical_treatment, Pembrolizumab, Institutional review board, Discontinuation, Clinical trial, Response Evaluation Criteria in Solid Tumors, Internal medicine, Adjuvant therapy, Medicine, business, Adverse effect, Neoadjuvant therapy

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::82ef96811ba08ac93d1a43925bc712fdTest
https://doi.org/10.1136/jitc-2020-sitc2020.0426Test

6

311 Phase II trial of lymphodepletion plus adoptive cell transfer with or without dendritic cell vaccination in patients with metastatic melanoma

المؤلفون: Jeniffer McQuade, Rodabe N. Amaria, Hussein Abdul-Hassan Tawbi, Chantal Saberian, Marie Andrée Forget, Gregory Lizée, Michael Davies, Chantale Bernatchez, Patrick Hwu, Roland L. Bassett, Cara Haymaker, Sapna Pradyuman Patel, Adi Diab, Michael K. Wong, Isabella C. Glitza, Cassian Yee

المصدر: Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5089182ad7d3fa0d4f02076173a7dd94Test
https://doaj.org/article/064c87c9ecf5438799789c15ab31529cTest

7

Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce

المصدر: Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 1 (2020)

مصطلحات موضوعية: 0301 basic medicine, Male, Cancer Research, medicine.medical_specialty, medicine.medical_treatment, Immunology, Programmed Cell Death 1 Receptor, 03 medical and health sciences, 0302 clinical medicine, Cancer immunotherapy, Position Article and Guidelines, Neoplasms, medicine, Biomarkers, Tumor, Immunology and Allergy, Humans, Intensive care medicine, RC254-282, Pharmacology, business.industry, Clinical study design, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Cancer, Immunotherapy, medicine.disease, Discontinuation, Blockade, Clinical trial, 030104 developmental biology, Drug development, 030220 oncology & carcinogenesis, oncology, Molecular Medicine, Female, business

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9f522809298c654239b55e7c89709a71Test
http://europepmc.org/articles/PMC7174063Test

8

Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma : safety run-in and biomarker cohorts of COMBI-i

المساهمون: University of Zurich, Dummer, Reinhard

مصطلحات موضوعية: 0301 basic medicine, Oncology, Male, Skin Neoplasms, Medizin, Cohort Studies, 0302 clinical medicine, Antineoplastic Agents, Immunological, Antineoplastic Combined Chemotherapy Protocols, Oximes, Clinical endpoint, Neoplasm Metastasis, Immune Checkpoint Inhibitors, Melanoma, Trametinib, MEK inhibitor, Imidazoles, 10177 Dermatology Clinic, General Medicine, Middle Aged, MAP Kinase Kinase Kinases, Treatment Outcome, 030220 oncology & carcinogenesis, Disease Progression, Biomarker (medicine), Female, medicine.drug, Adult, Proto-Oncogene Proteins B-raf, medicine.medical_specialty, Pyridones, Mutation, Missense, 610 Medicine & health, Genetics and Molecular Biology, Pyrimidinones, Antibodies, Monoclonal, Humanized, General Biochemistry, Genetics and Molecular Biology, 03 medical and health sciences, Young Adult, 1300 General Biochemistry, Genetics and Molecular Biology, Internal medicine, medicine, Biomarkers, Tumor, Humans, Protein Kinase Inhibitors, Aged, business.industry, Dabrafenib, medicine.disease, Clinical trial, Regimen, 030104 developmental biology, General Biochemistry, business

وصف الملف: 870_Dummer_R._et_al._Combined_PD-1,_BRAF_and_MEK_inhibition_in_advanced_BRAF-mutant_melanoma_Nature_Medicine_2020.pdf - application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6b17ee96d80a3281cdd7448c58c9110fTest
https://www.ncbi.nlm.nih.gov/pubmed/33020648Test

9

Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial

المصدر: The Lancet Oncology. 19:181-193

مصطلحات موضوعية: 0301 basic medicine, Oncology, Skin Neoplasms, medicine.medical_treatment, law.invention, 0302 clinical medicine, Randomized controlled trial, law, Antineoplastic Combined Chemotherapy Protocols, Oximes, Clinical endpoint, Melanoma, Neoadjuvant therapy, Trametinib, Academic Medical Centers, education.field_of_study, Imidazoles, Standard of Care, Middle Aged, Prognosis, Texas, Neoadjuvant Therapy, Treatment Outcome, Chemotherapy, Adjuvant, 030220 oncology & carcinogenesis, medicine.drug, Adult, medicine.medical_specialty, Pyridones, Population, Pyrimidinones, Cancer Care Facilities, Risk Assessment, Disease-Free Survival, 03 medical and health sciences, Internal medicine, Confidence Intervals, medicine, Adjuvant therapy, Humans, Neoplasm Invasiveness, education, Aged, Neoplasm Staging, business.industry, Dabrafenib, Mohs Surgery, Survival Analysis, Clinical trial, 030104 developmental biology, business

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ab690f1022d28461b6e4ffd40f8fb279Test
https://doi.org/10.1016/s1470-2045Test(18)30015-9

10

Intrathecal (IT) and intravenous (IV) nivolumab (N) for metastatic melanoma (MM) patients (pts) with leptomeningeal disease (LMD)

المصدر: Journal of Clinical Oncology. 39:9519-9519

مصطلحات موضوعية: Oncology, Cancer Research, medicine.medical_specialty, Metastatic melanoma, business.industry, Intrathecal, Clinical trial, Internal medicine, medicine, Overall survival, LEPTOMENINGEAL DISEASE, Nivolumab, business

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::e56e45157fae04e1f6e51791974c94aaTest
https://doi.org/10.1200/jco.2021.39.15_suppl.9519Test

تنقيح النتائج